This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Trial of Naltrexone and Dextromethorphan for Gulf War Illness (GWI Treatment)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
William J. Meggs, East Carolina University
ClinicalTrials.gov Identifier:
NCT02206490
First received: August 24, 2012
Last updated: March 2, 2016
Last verified: March 2016
  Purpose
Veterans of the 1991 Gulf War who developed Gulf War Illness are being studied. Treatments with FDA approved generic drugs are being administered to see if they help with the symptoms of Gulf War Illness, such as chronic fatigue; difficulty with memory, concentration, and thinking; widespread chronic pain; and autonimic dysfunction. Drugs to be tested are dextromethorphan and naltrexone.

Condition Intervention Phase
Gulf War Illness Drug: naltrexone Drug: Dextromethorphan Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Trial of Naltrexone and Dextromethorphan for Gulf War Veterans Illnesses

Resource links provided by NLM:


Further study details as provided by William J. Meggs, East Carolina University:

Primary Outcome Measures:
  • Symptoms Scores [ Time Frame: 28 weeks approximately ]

    Symptoms of Gulf War Illness will be scored by participants using a ten center meter scale.

    Scores will be collected at the end of 12 weeks/16 weeks/28weeks



Secondary Outcome Measures:
  • SF-36 [ Time Frame: 28 weeks approximately ]

    Subjects will complete a standard health assessment tool, the SF-36, at the end of each course of therapy.

    Scores will be collected at 12 weeks/16 weeks/28 weeks


  • Connors Continuous Performance Test [ Time Frame: 28 weeks approximately ]

    Subjects will take the Connors Continuous Performance Test at the end of each course of study drug or placebo.

    Scores will be collected at 12 weeks/16 weeks/28 weeks



Enrollment: 60
Study Start Date: January 2012
Study Completion Date: January 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Naltrexone Study Drug
Subjects will take naltrexone 4.5 mg daily for three months.
Drug: naltrexone
Randomized controlled trial of naltrexone for Gulf War Illness.
Placebo Comparator: Naltrexone placebo
Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
Drug: naltrexone
Randomized controlled trial of naltrexone for Gulf War Illness.
Active Comparator: dextromethrophan study drug
subjects will take a sustained release dextromethorphan pill twice a day.
Drug: Dextromethorphan
Randomized controlled trial of dextromethorphan for Gulf War Illness
Placebo Comparator: dextromethoprhan placebo
Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
Drug: Dextromethorphan
Randomized controlled trial of dextromethorphan for Gulf War Illness

Detailed Description:

Gulf war veterans' illnesses comprise distinct clusters of symptom-defined illnesses for which there are neither diagnostic tests nor effective treatments. Gulf war veterans had variable exposures to a number of chemicals, including organophosphate insecticides, pyrethrum-related insecticides, DEET, Pyridostigmine bromide, smoke from oil well fires, and Sarin gas. Gulf war veterans' illnesses may reflect an inflammatory cycle involving the brain which may be a common mechanism of many neurological conditions, whether initiated by toxic exposures, infection, or trauma. In this theory, central nervous system inflammation initiated by toxic exposures and sometimes exacerbated by subsequent exposures is a component of illness hypothesized to explain the neurological manifestations. Substance P release at sensory nerve endings is an explanation for the peripheral pain manifestations of illness.

This theory suggests that novel anti-inflammatory drugs may be of benefit in symptom-defined illnesses related to a cycle of inflammation. Dr. J. S. Hong's laboratory at the National Institute of Environmental Health Sciences has demonstrated that Morphine-related analogs, including Naltrexone and Dextromethorphan, have great potency in anti-inflammation and neuroprotective effects. Naltrexone is a safe and readily available generic medication. Dextromethorphan is also a safe and readily available generic medication that is available without a prescription as a cough medication. Results from several clinical trials showed that Naltrexone is effective in several inflammation-related diseases, such as neurogenic pain, movement disorders, etc. In addition, there were no obvious side effects in patients taking this drug for six months. This project will conduct randomized double-blinded studies for treating ill Gulf war veterans with Naltrexone and Dextromethorphan. Laboratory tests for markers of inflammation including neurogenic inflammation will be performed pre- and post-treatment, to see if these markers are elevated and if so, to see if treatment modulates these markers.

Ill Gulf veterans will be recruited through the media, veterans groups, and individual veteran activists. A screening telephone interview will be performed to determine if the veterans meet a modified Kansas case definition for inclusion. Those veterans who meet study criteria will be invited to participate. Eligible veterans will be invited for an initial visit that will consist of obtaining written informed consent, a medical history, physical examination, and laboratory testing. Institutional review board approval of the study will be in place. The pharmacy staff at the institution will prepare the medications and placebo in identical capsules.

  Eligibility

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Served in the Gulf War and developed the symptoms of Gulf War Illness as described by the modified Kansas Case Definition

Exclusion Criteria:

  • Pregnant women, nursing mothers, individuals requiring medications that have drug interactions with dextromethorphan or naltrexone, cancer not in remission, chronic infectious disease, liver disease, lupus, multiple sclerosis, stroke, under current treatment for schizophrenia, bipolar disorder/manic depression, and depression.
  • Those with a history of current illicit drug use will be excluded. Individuals who have had recent surgery will not be enrolled until they have completely recovered from the surgery.
  • Subjects participating in other clinical trials will be excluded.
  • Those enrolled recently in a clinical trial will be enrolled after a washout period of one month.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02206490

Locations
United States, North Carolina
Brody School of Medicine a East Carolina Univesity
Greenville, North Carolina, United States, 27834
Sponsors and Collaborators
East Carolina University
  More Information

Additional Information:
Responsible Party: William J. Meggs, Professor, East Carolina University
ClinicalTrials.gov Identifier: NCT02206490     History of Changes
Other Study ID Numbers: 090562
Study First Received: August 24, 2012
Last Updated: March 2, 2016

Keywords provided by William J. Meggs, East Carolina University:
Gulf War Illness
treatment
dextromethorphan
naltrexone

Additional relevant MeSH terms:
Naltrexone
Dextromethorphan
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 28, 2017